Alpelisib
Alpelisib (BYL-719) is an orally bioavailable, potent, and selective PI3Kα inhibitor (IC50=5 nM) with significantly lower activity against other PI3K isoforms. It demonstrates antitumor efficacy in both in vitro and in vivo models, specifically targeting cancers harboring PIK3CA mutations.
Product Specifications
CAS Number
1217486-61-7
Product Name Alternative
Inhibitor, mutant, inhibit, metastasis, breast, antineoplastic, cancer, BYL 719, BYL719, BYL-719, Alpelisib, AKT, Phosphoinositide 3-kinase, PI3K, phosphorylation, PIK3CA, PI3Kα, p110α
Field of Research
Pharmacology & Drug Discovery, Signal Transduction
Purity
98.00% (May vary between batches)
Solubility
Ethanol:2 mg/mL (4.53 mM) ; DMSO:240 mg/mL (543.64 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:8.2 mg/mL (18.57 mM)
Smiles
Cc1nc (NC (=O) N2CCC[C@H]2C (N) =O) sc1-c1ccnc (c1) C (C) (C) C (F) (F) F
Molecular Formula
C19H22F3N5O2S
Molecular Weight
441.47
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog